实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (3): 356-359.doi: 10.3969/j.issn.1672-5069.2023.03.014

• 非酒精性脂肪性肝病 • 上一篇    下一篇

T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨*

赵玲玲, 王贝贝, 姚勇利, 郑有花, 李亚楠   

  1. 810002 西宁市 青海大学附属青海省人民医院内分泌二科(赵玲玲,王贝贝,姚勇利,李亚楠);消化内科(郑有花)
  • 收稿日期:2022-07-27 出版日期:2023-05-10 发布日期:2023-05-08
  • 通讯作者: 姚勇利,E-mail:yaoylqh@126.com
  • 作者简介:赵玲玲,女,33岁,医学硕士,主治医师。研究方向:内分泌学。E-mail:zlingling0913@126.com
  • 基金资助:
    *青海省自然科学基金资助项目(编号:2017-ZJ-914)

Serum resistin and triacylglycerol glucose index in patients with T2DM and non-alcoholic fatty liver: their combination for progressive fibrosis

Zhao Lingling, Wang Beibei, Yao Yongli, et al.   

  1. Second Section, Department of endocrinology, Provincial People's Hospital, Affiliated to Qinghai University, Xining 810002,Qinghai Province, China
  • Received:2022-07-27 Online:2023-05-10 Published:2023-05-08

摘要: 目的 探讨2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者进展性肝纤维化的血清指标评估方法。方法 2019年3月~2022年2月青海省人民医院收治的204例T2DM合并NAFLD患者,依据NAFLD纤维化评分(NFS)诊断进展性肝纤维化。采用ELISA法检测血清抵抗素水平,常规检测空腹三酰甘油和空腹血糖,计算三酰甘油葡萄糖(TyG)指数,应用多因素Logistic回归分析影响T2DM合并NAFLD患者进展性肝纤维化发生的危险因素,应用受试者工作特征曲线(ROC)下面积(AUC)评估血清抵抗素联合TyG指数的诊断效能。结果 在204例T2DM合并NAFLD患者中,发现存在进展性肝纤维化者31例(15.2%);进展性肝纤维化组年龄、糖尿病病程、HOMA-IR、血清抵抗素和TyG指数显著大于或长于非进展性肝纤维化组(P<0.05),而估算的肾小球滤过率(eGFR)则显著低于非进展性肝纤维化组(P<0.05); 多因素Logistic回归分析显示,年龄(OR=2.901,95%CI:1.042~5.238)、血清抵抗素(OR=3.404,95%CI:1.874~9.435)和TyG指数(OR=2.965,95%CI:1.258~6.439)均为影响T2DM合并NAFLD患者发生进展性肝纤维化的独立危险因素(P<0.05);ROC曲线分析结果显示,血清抵抗素、TyG指数或两者联合预测T2DM合并NAFLD患者发生进展性肝纤维化的灵敏度分别为71.0%、74.2%和71.0%(三指标无显著性差异,P>0.05),而特异度分别为76.3%、78.2%和96.5%,联合检测预测更好(P<0.05)。结论 联合检测血清抵抗素和TyG指数预测T2DM合并NAFLD患者发生进展性肝纤维化有一定的临床应用价值,可帮助临床医生无创评估病情进展,值得进一步研究。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 进展性肝纤维化, 抵抗素, 三酰甘油葡萄糖指数, 诊断

Abstract: Objective The purpose of this study was to investigate the changes of serum resistin and triacylglycerol glucose (TyG) index in patients with type 2 diabetes mellitus (T2DM) and concomitant non-alcoholic fatty liver diseases (NAFLD) to predict progressive liver fibrosis. Methods A total of 204 patients with T2DM and NAFLD were encountered in our hospital between March 2019 and February 2022, and the progressive liver fibrosis was evaluated by NAFLD fibrosis score (NFS). Serum resistin levels were detected by ELISA, and blood triacylglycerol and gl ucose levels were obtained routinely and the TyG index werecalculated. The multivariate Logistic regression analysis was applied to reveal the risk factors for the occurrence of progressive liver fibrosis in T2DM and NAFLD.The area under the receiver operating characteristic curves (AUC) was applied to evaluate the predictive performance of serum resistin and TyG index on the occurrence of progressive liver fibrosis in patients with T2DM and NAFLD. Results Out of the 204 patients with T2DM and NAFLD, the progressive liver fibrosis was found in 31 cases(15.2%); the age, disease history of diabetes, HOMA-IR , serum resistin level and TyG index in patients with progressive liver fibrosis were significantly higher or longer than in patients without(P<0.05), while the estimated glomerular filtration rate(eGFR) was significantly lower than in those without (P<0.05); the multivariate Logistic regression analysis showed that the age (OR=2.901, 95%CI: 1.042-5.238), serum resistin level (OR=3.404, 95%CI:1.874-9.435) and the TyG index (OR=2.965, 95%CI:1.258-6.439) were all the independent risk factors for the occurrence of progressive liver fibrosis in patients with T2DM and NAFLD(P<0.05); the ROC analysis demonstrated that the sensitivities were 71.0%, 74.2% and 71.0%(P>0.05), and the specificities were 76.3%, 78.2% and 96.5% (P<0.05) when serum resistin level, the TyG index or the combination of the two parameters was applied to predict the existence of progressive liver fibrosis. Conclusion Serum resistin levels and TyG index are related to the occurrence of progressive liver fibrosis in patients with T2DM and NAFLD, and the combination of the two parameters might be used to predict severe liver fibrosis in this setting and help clinicians to make decisions for early management.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes, Progressive liver fibrosis, Resistin, Triacylglycerol glucose index, Diagnosis